Log in

Geron Stock Price, News & Analysis (NASDAQ:GERN)

$1.43
-0.06 (-4.03 %)
(As of 10/21/2019 01:31 AM ET)
Today's Range
$1.42
Now: $1.43
$1.50
50-Day Range
$1.29
MA: $1.43
$1.59
52-Week Range
$0.95
Now: $1.43
$2.14
Volume1.13 million shs
Average Volume1.61 million shs
Market Capitalization$269.44 million
P/E RatioN/A
Dividend YieldN/A
Beta2.51
Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GERN
CUSIP37416310
Phone650-473-7700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.07 million
Book Value$0.95 per share

Profitability

Net Income$-27,020,000.00
Net Margins-5,328.80%

Miscellaneous

Employees17
Market Cap$269.44 million
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable

Receive GERN News and Ratings via Email

Sign-up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.


Geron (NASDAQ:GERN) Frequently Asked Questions

What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) issued its earnings results on Thursday, August, 1st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.09) by $0.01. The biopharmaceutical company had revenue of $0.10 million for the quarter, compared to analysts' expectations of $0.20 million. Geron had a negative return on equity of 22.33% and a negative net margin of 5,328.80%. View Geron's Earnings History.

When is Geron's next earnings date?

Geron is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Geron.

What price target have analysts set for GERN?

5 analysts have issued 12-month price targets for Geron's shares. Their predictions range from $3.00 to $4.50. On average, they anticipate Geron's share price to reach $3.90 in the next year. This suggests a possible upside of 172.7% from the stock's current price. View Analyst Price Targets for Geron.

What is the consensus analysts' recommendation for Geron?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Geron.

Has Geron been receiving favorable news coverage?

News stories about GERN stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Geron earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Geron.

Who are some of Geron's key competitors?

What other stocks do shareholders of Geron own?

Who are Geron's key executives?

Geron's management team includes the folowing people:
  • Dr. John A. Scarlett, CEO, Pres & Chairman (Age 68)
  • Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 50)
  • Dr. Andrew J. Grethlein, Exec. VP & COO (Age 55)
  • Mr. Stephen N. Rosenfield, Exec. VP, Chief Legal Officer & Corp. Sec. (Age 69)
  • Ms. Melissa A. Kelly Behrs, Exec. VP & Chief Bus. Officer (Age 55)

Who are Geron's major shareholders?

Geron's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Summit X LLC (0.05%). Company insiders that own Geron stock include Melissa Kelly Behrs, Robert J Spiegel and Stephen Rosenfield. View Institutional Ownership Trends for Geron.

Which major investors are buying Geron stock?

GERN stock was bought by a variety of institutional investors in the last quarter, including Summit X LLC. View Insider Buying and Selling for Geron.

How do I buy shares of Geron?

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Geron's stock price today?

One share of GERN stock can currently be purchased for approximately $1.43.

How big of a company is Geron?

Geron has a market capitalization of $269.44 million and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,020,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. Geron employs 17 workers across the globe.View Additional Information About Geron.

What is Geron's official website?

The official website for Geron is http://www.geron.com/.

How can I contact Geron?

Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]


MarketBeat Community Rating for Geron (NASDAQ GERN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  389 (Vote Outperform)
Underperform Votes:  313 (Vote Underperform)
Total Votes:  702
MarketBeat's community ratings are surveys of what our community members think about Geron and other stocks. Vote "Outperform" if you believe GERN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GERN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/21/2019 by MarketBeat.com Staff

Featured Article: Sell-Side Analysts

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel